Novo Nordisk Looks To Bring AI/ML To Cardiometabolic Disease In Valo Health Deal

Deal Snapshot: The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform.